RGEN said it would buy Biolife Solutions (BLFS) in a cash-and-stock deal valued at about $1.5B, to expand its presence in the fast-growing c

RGEN said it would buy Biolife Solutions (BLFS) in a cash-and-stock deal valued at about $1.5B, to expand its presence in the fast-growing cell therapy market; Biolife shareholders will receive $11.25 in cash and 0.1442 shares of Repligen for each share, valuing the cell-and-gene-therapy maker at $31 per share.